XPENG To Attend IAA Mobility 2023 as EU Deliveries Begin
30.8.2023 13:45:00 EEST | Business Wire | Press release
XPeng Motors (“XPENG” or the “Company,” NYSE: XPEV and HKEX: 9868), a leading Chinese smart electric vehicle (“Smart EV”) company, today announced the beginning of P7 deliveries in four key European markets and its participation in IAA Mobility 2023, Munich, Germany.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230830333578/en/
European P7 Delivery
Outstanding Smart EVs for Europe
XPENG G9 and P7 were launched in February this year, with excitement around the brand and positive feedback continuing to build up with deliveries beginning.
In June, XPENG G9 broke the charging record at the two-day NAF (Norwegian Automobile Federation) and Motor EV Summer test, also known as El-Prix 2023, reaching a peak charging power of 319 kW. This also represented the test's highest average charging power at 212 kW, allowing drivers to charge up to 100 km of range in just five minutes. G9 and P7 occupied the top two spots in the range test, which measures the real-world deviation rate compared to the stated WLTP range; there was an increase of 13% and 10% for G9(4WD) and P7(4WD), respectively.
As a spacious sports sedan, XPENG P7's cabin provides exceptional comfort, which is surrounded by a sleek exterior epitomizing XPENG's Dynamic Aesthetics design language. Deliveries of P7 recently commenced, with the first batches of vehicles having arrived at XPENG's delivery centers in Lørenskog, Norway; Järfälla, Sweden; Hillerød, Denmark; and Badhoevedorp, The Netherlands.
"We’re delighted that customers who placed orders at the very beginning can finally drive P7 on Europe’s roads,” said Eric Xu, VP of International Markets XPENG. “The feedback has been positive so far, and with our rapidly growing network, we’re very optimistic about our future on the continent.”
Drive With Confidence
As part of the company's dedication to delivering superior customer experiences, XPENG is offering a comprehensive service agreement, which includes an eight-year warranty for the vehicle's battery, as well as a seven-year/160,000 km extended warranty for all orders placed in 2023.
Deliveries of G9 will begin in the coming months as XPENG's network of authorized agencies and partners expands, which will optimize sales, delivery, and servicing processes to create a seamless customer journey.
Learn More About XPENG P7 for Europe
https://www.heyxpeng.com/nl/p7
https://www.heyxpeng.com/dk/p7
https://www.heyxpeng.com/no/p7
https://www.heyxpeng.com/se/p7
XPENG at IAA Mobility 2023
As a technology pioneer in the mobility industry, XPENG will participate in the world's largest mobility event this year, IAA Mobility, on September 4–10, 2023 in Munich. XPENG's agenda is as follows:
-
Pre-IAA XPENG Press Conference
- H4 Hotel Munich Messe
- Monday, September 4, 11 am–12 pm
-
IAA Summit Panel: Unleashing the Integrated Smart Ecosystem
- Blue Stage
- A discussion on how intelligent and autonomous vehicles are transforming the industry and our overall mobility experience
- Featuring Co-President and Vice Chairman Brian Gu
- Tuesday, September 5, 3 pm–3:45 pm
-
Open Space Activation with Product Displays
- Konigsplatz, Stand KP155
- Tuesday, September 5 – Sunday, September 10, 10 am–8 pm
-
P7 and G9 Test Drives at Blue Lane*
-
Near Hall C3, Munich Messe
- Monday, September 4, 8 am–6 pm
- Tuesday, September 5 – Friday, September 8, 9 am–6 pm
-
Near Konigsplatz
- Tuesday, September 5 – Saturday, September 9, 10 am–8 pm
- Sunday, September 10, 10 am–5 pm
-
Near Hall C3, Munich Messe
*Subject to pre-booking
Follow XPENG at IAA Mobility 2023
About XPENG
XPENG is a global smart electric vehicle company founded in 2014 in Guangzhou, China, developing clean, intuitive, and creative mobility solutions. With industry-leading R&D facilities, XPENG is bringing vehicles with superior safety, electric efficiency, and on-road performance to markets across the globe. The company is constantly working to advance its core technology offering, including autonomous driving capabilities, SEPA 2.0, and captivating in-car infotainment systems. XPENG has headquarters in Guangzhou and Amsterdam, with additional offices in Beijing, Shanghai, and Silicon Valley.
Visit heyxpeng.com for more information.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230830333578/en/
Contact information
For Media Enquiries: pr@xiaopeng.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
